An open label study of the safety and efficacy of a single dose of weekly chloroquine and azithromycin administered for malaria prophylaxis in healthy adults challenged with 7G8 chloroquine-resistant Plasmodium falciparum in a controlled human malaria infection model
Abstract
Malaria remains the top infectious disease threat facing the U.S. military in many forward operating environments. Compliance with malaria chemoprophylaxis remains a critical component in preventing malaria in the deployed Service Member. Studies of previous military operations show that compliance is consistently higher with weekly versus daily dosing regimens. Current FDA approved weekly chemoprophylaxis options have contraindications that can limit prescribing. The combination of chloroquine (CQ) with azithromycin (AZ) has previously been shown to be an efficacious treatment option for malaria, has pharmacokinetics compatible with weekly dosing, and has shown synergy when combined in vitro.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Sep 16, 2020
- Source ID
- 10.1186/s12936-020-03409-z
Entities
People
- April Sikaffy
- Chau Vuong
- Christine K Lee
- Daniel J Selig
- Donna Tosh
- Elizabeth H. Duncan
- Jack Hutter
- James E. Moon
- Jason Bennett
- Jason Sousa
- Jeffrey Livezey
- Jesse Deluca
- Kristin Mills
- Lucas Poon
- Mara Kreishman-deitrick
- Martha Sedegah
- Melinda Hamer
- Meshell Morrison
- Paige Waterman
- Patrick Twomey
- Susan Cicatelli
- Thomas Oliver
Organizations
- Congressionally Directed Medical Research Programs